FDA-Industry Relations Faulted As 'Revolving Door' In BMJ Report
Academic authors say that more than half of FDA medical reviewers leave to either work or consult to industry; experts chime in with mixed reactions to the findings.
You may also be interested in...
One of the faces of FDA's effort to recruit senior leaders from outside its walls has decided to return to industry.
After Office of Generic Drugs Deputy Director Gordon Johnston left FDA, he joined GPhA and 'tricked' a former colleague into sharing info on generic Lovenox on behalf of a hedge fund he was secretly working for, SEC says.
In Pink Sheet's exclusive interview, new commissioner says FDA will tap knowledge beyond its walls, without compromising agency independence.